New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
05:53 EDTBMY, AMGN, GILDDrug firms shift revenue abroad to lower taxes, WSJ reports
A number of big drug companies pay effective tax rates of 20% or more. Now they're taking steps to lower their taxes significantly, helping their bottom lines, reports the Wall Street Journal. While they don't specify their strategies, details can vary. But the efforts typically involve shifting revenue overseas where it can be taxed at a lower rate than in the U.S., experts say. Some companies also noted the tax benefit they will receive this year from a federal tax credit for research and development.Reference Link
News For BMY;GILD;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 13, 2015
12:55 EDTAMGNAmgen repeats FY15 adjusted EPS view $9.05-$9.40, consensus $9.29
Subscribe for More Information
12:40 EDTAMGNAmgen off highs after Express Scripts CEO talks PCSK9 costs
Subscribe for More Information
12:27 EDTBMYDOJ, EPA report proposed settlement regarding cleanup of Warren County, NJ site
Subscribe for More Information
12:15 EDTGILDExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTGILDExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information
11:43 EDTGILDGilead says negotiations ongoing with major U.S. payors for Harvoni
Subscribe for More Information
11:10 EDTGILDGilead drops, levels to watch
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
08:09 EDTBMYBristol-Myers price target raised to $72 from $66 at Leerink
Leerink raised its price target for Bristol-Myers to $72 saying the earlier stop of the Opdivo trial affirms the drug's potential survival benefits across multiple cancers. Leerink says it now has increased confidence in positive readouts for Bristol's upcoming survival studies in non-squamous non-small cell lung cancer and kidney cancer. The firm reiterates an Outperform rating on the stock.
08:05 EDTBMYBristol-Myers Eli Lilly enter clinical collaboration pact for Opdivo combo
Subscribe for More Information
07:42 EDTAMGN, GILD, BMYJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
16:10 EDTAMGNAmgen, MD Anderson announce agreement to develop BiTE
Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen's bispecific T cell engager, or BiTE, antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells. The research agreement will identify targets for this therapy in myelodysplastic syndrome, or MDS, a bone marrow disorder in which the body does not produce sufficient healthy blood cells. MDS affects primarily older adults over age 60 and can cause severe anemia, potentially leading to development of acute myelogenous leukemia, a blood cell cancer.
09:34 EDTGILDActive equity options trading
Subscribe for More Information
09:00 EDTBMYBristol-Myers price target raised to $70 from $62 at Argus
Subscribe for More Information
08:37 EDTBMYShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:15 EDTBMYSeattle Genetics announces clinical trial collaboration with Bristol-Myers
Subscribe for More Information
08:06 EDTBMYBristol-Myers shares expected to trade up around 10% at JPMorgan
JPMorgan expects shares of Bristol-Myers to trade up around 10% after the company announced that its Phase III trial of Opdivo in 2L squamous non-small cell lung cancer is stopping early due to efficacy. The firm views the news as a "clear positive" that sets up a potential 2015 filing and launch for the product in the 2L squamous market. It reiterates an Overweight rating on shares of the Bristol-Myers. The stock is up 7% to $64.25 in pre-market trading.
07:17 EDTAMGNJPMorgan to hold a conference
Subscribe for More Information
05:26 EDTBMYBristol-Myers up 5.6% after Opdivo Phase 3 study meets primary endpoint
Subscribe for More Information
05:06 EDTBMYBristol-Myers Opdivo Phase 3 study met primary endpoint
Bristol-Myers Squibb announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer, or NSCLC, was stopped early because an assessment conducted by the independent Data Monitoring Committee, or DMC, concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm. The company will share these data – which for the first time indicate a survival advantage with an anti-PD1 immune checkpoint inhibitor in lung cancer – with health authorities. CheckMate -017 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -017 data and work with investigators on the future presentation and publication of the results.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use